Ribomic

Ribomic EBIT Growth

The Year-over-Year EBIT Growth of Ribomic (4591.T) as of Oct 31, 2026 is -14.90 %. In the previous year, Year-over-Year EBIT Growth was 5.88 % — a change of -353.52% (lower).

EBIT Growth

-14.90 %

YoY

-353.52%

Last updated:

Year-over-Year EBIT Growth of Ribomic is 2026 -14.90 % . Year-over-Year EBIT Growth of Ribomic was 2025 5.88 % . It decreases by -353.52% lower compared to the previous year.

The Ribomic EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
-3.19 JPY
Jan 1, 2020
1.51 JPY
Jan 1, 2021
-35.54 JPY
Jan 1, 2022
-41.02 JPY
Jan 1, 2023
-2.17 JPY
Jan 1, 2024
37.50 JPY
Jan 1, 2025
5.88 JPY
Jan 1, 2026
-14.90 JPY
The Ribomic EBIT Growth history
YEAREBIT GrowthYoY
-14.90 %-353.52%
5.88 %-84.33%
37.50 %-1,828.51%
-2.17 %-94.71%
-41.02 %+15.41%
-35.54 %-2,449.97%
1.51 %-147.37%
-3.19 %-77.99%
-14.50 %-69.54%
-47.62 %-99.45%
-8,714.71 %-8,724.44%
101.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Year-over-Year EBIT Growth of Ribomic is -14.90 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Ribomic since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Ribomic

All Key Metrics — Ribomic